Mostrando resultados 11 a 20 de 20
< Anterior
Vista previa | Fecha de publicación | Título | Autor(es) | Acceso |
![Impact of CYP2D6 genotype on opioid use disorder deprescription an observational prospective study in chronic pain with sex-differences.pdf.jpg](/jspui/retrieve/ff607586-26c5-4511-a50c-c94782d71227/Impact%20of%20CYP2D6%20genotype%20on%20opioid%20use%20disorder%20deprescription%20an%20observational%20prospective%20study%20in%20chronic%20pain%20with%20sex-differences.pdf.jpg) | 2023 | Impact of CYP2D6 genotype on opioid use disorder deprescription: an observational prospective study in chronic pain with sex-differences | Muriel, Javier; Barrachina, Jordi; Del Barco, Guillermo; Carvajal, Cristian; Escorial, Mónica; Margarit, César; Ballester, Purificación; Peiró, Ana María | ![](/image/openAccess.png) |
![Long-term deprescription in chronic pain and opioid use disorder patients. Pharmacogenetic and sex differences.pdf.jpg](/jspui/retrieve/442d251d-8781-4a09-b495-e3bbda10e4df/Long-term%20deprescription%20in%20chronic%20pain%20and%20opioid%20use%20disorder%20patients.%20Pharmacogenetic%20and%20sex%20differences.pdf.jpg) | 18-nov-2022 | Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences | Muriel, Javier; Escorial, Mónica; Margarit, César; Barrachina, Jordi; Carvajal, Cristian; Morales, Domingo; Peiró, Ana | ![](/image/openAccess.png) |
![OPRM1 influence on and effectiveness of an individualized.pdf.jpg](/jspui/retrieve/f0912f0d-190d-4252-9401-6e74eb01cbdc/OPRM1%20influence%20on%20and%20effectiveness%20of%20an%20individualized.pdf.jpg) | 2018 | OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients | Muriel, Javier; Margarit, César; Planelles, Beatriz; Serralta, María J.; Puga, Carmen; Inda, María del Mar; Cutillas, Esperanza; Morales, Domingo; Horga, José F. | ![](/image/closedAccess.png) |
![Oxycodonenaloxone - naloxone versus tapentadol in real-world chronic non-cancer pain management.an observational and pharmacogenetic study.pdf.jpg](/jspui/retrieve/49e3f51c-59c2-43d1-9d15-6d348e3d5cf2/Oxycodonenaloxone%20-%20naloxone%20versus%20tapentadol%20in%20real-world%20chronic%20non-cancer%20pain%20management.an%20observational%20and%20pharmacogenetic%20study.pdf.jpg) | jun-2022 | Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study | Barrachina, Jordi; Margarit, César; Muriel, Javier; López‑Gil, Santiago; López Gil, Vicente; Vara-González, Amaya; Planelles, Beatriz; Inda, María del Mar; Morales, Domingo; Peiró, Ana | ![](/image/openAccess.png) |
![Oxycodonenaloxone.naxolone versus tapentadol in real world chronic non‑cancer pain.pdf.jpg](/jspui/retrieve/6dff66a3-3891-4c74-9646-8c79f0d0e88e/Oxycodonenaloxone.naxolone%20%20versus%20tapentadol%20in%20real%20world%20chronic%20non%e2%80%91cancer%20pain.pdf.jpg) | 2022 | Oxycodone/naloxone versus tapentadol in real‑world chronic non‑cancer pain management: an observational and pharmacogenetic study | Barrachina, Jordi; Margarit, Cesar; Muriel, Javier; López‑Gil, Santiago; López Gil, Vicente; Vara-González, Amaya; Planelles, Beatriz; Inda, María del Mar; Morales, Domingo; Peiró, Ana María | ![](/image/openAccess.png) |
![Pharmacogenetic Guided Opioid Therapy Improves Chronic.pdf.jpg](/jspui/retrieve/1772878b-270e-4cd7-bc03-a7cb5fee6471/Pharmacogenetic%20Guided%20Opioid%20Therapy%20Improves%20Chronic.pdf.jpg) | 2023 | Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study | Agulló, Laura; Aguado, Isidro; Muriel, Javier; Margarit, César; Gómez, Alba; Escorial, Mónica; Sánchez, Astrid; Fernández, Alicia; Peiró, Ana | ![](/image/openAccess.png) |
![Pharmacogenetics and prediction of adverse events in.pdf.jpg](/jspui/retrieve/57275c95-8b6e-4e03-a7db-9b305d1d5d13/Pharmacogenetics%20and%20prediction%20of%20adverse%20events%20in.pdf.jpg) | 2018 | Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients | Muriel, Javier; Margarit, César; Barrachina, Jordi; Ballester, Purificación; Flor, Andrea; Morales, Domingo; Horga, José F.; Fernández, Eduardo; Peiró, Ana | ![](/image/closedAccess.png) |
![Sex-Differences in Pain and Opioid Use Disorder Management.pdf.jpg](/jspui/retrieve/cdaa89cd-f9f5-4e9f-841d-30bf0c32ba97/Sex-Differences%20in%20Pain%20and%20Opioid%20Use%20Disorder%20Management.pdf.jpg) | 2022 | Sex-Differences in Pain and Opioid Use Disorder Management: A Cross-Sectional Real-World Study | Escorial, Mónica; Muriel, Javier; César, Margarit; Laura, Agulló; Domingo, Morales; Peiró, Ana | ![](/image/openAccess.png) |
![The challenge of detecting adverse events in adults with autism.pdf.jpg](/jspui/retrieve/d98d8190-390a-400b-b2d5-c2701c7e0b73/The%20challenge%20of%20detecting%20adverse%20events%20in%20adults%20with%20autism.pdf.jpg) | may-2021 | The challenge of detecting adverse events in adults with autism spectrum disorder who have intellectual disability | Ballester, Purificación; Espadas, Cristina; Londoño, Ana C.; Almenara, Susana; Aguilar, Víctor; Belda, César; Pérez, Enrique; Muriel, Javier; Peiró, Ana | ![](/image/openAccess.png) |
![Tesis Muriel Serrano, Javier.pdf.jpg](/jspui/retrieve/6ba1dab0-1810-49f2-92e6-5007dd9bd6dd/Tesis%20Muriel%20Serrano%2c%20Javier.pdf.jpg) | 26-jul-2019 | Tratamiento del trastorno por consumo de opioides de prescripción, en pacientes con dolor crónico no oncológico: efectividad, seguridad y marcadores farmacogenéticos | Muriel, Javier | ![](/image/openAccess.png) |